Schizophrenia (SCZ) is a debilitating mental disorder with various causes involving complex interactions between genetic factors and environmental agents. The immune system plays a vital role in the pathology and function of the nervous system. Interleukin 35 (IL-35) is a regulatory and anti-inflammatory cytokine that can prevent autoimmune and inflammatory diseases. This study aimed to investigate the role of autoantibodies against some central nervous system (CNS) antigens and IL-35 serum levels in patients with Schizophrenia. This case-control study involved 80 participants. The serum levels of IL-35 were measured by enzyme-linked immunosorbent assay and the autoantibodies in the CNS by indirect immunofluorescence assay (IFA). The serum levels of IL-35 were decreased in patient groups compared to healthy subjects. Autoantibodies against N-methyl-D-aspartate receptor (NMDAR) and myelin-associated glycoprotein (MAG) were positive in 15% (6/40) and 7. 5% (3/40), respectively,however, no antibodies against myelin, aquaporin-4 (AQP4), myelin oligodendrocyte glycoprotein (MOG), voltage-gated potassium channel (VGKC), α,-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR), γ,-butyric acid receptor type B1 γ,-butyric acid receptor type B1 (GABABR), antidipeptidyl peptidase-like protein-6 (DPPX), immunoglobulin-like cell adhesion molecule 5 (IgLON5), Glycine receptor (R) and acetylcholine receptor (Ach R) were detected (No statistics were computed). We found that decreased serum IL-35 levels and the existence autoantibodies against NMDAR antigen may contribute to the pathogenesis of SCZ.

Background: Allergic asthma is believed to be a T helper 2 cell (Th2) preponderant response caused by airway hyper-responsiveness. Interleukin-35 (IL-35) is a newly discovered anti-inflammatory cytokine. Objective: To determine whether the expression of IL-35 is associated with type-2 inflammation in children with asthma exacerbations. Methods: Thirty children (6-12 years old) with acute allergic asthma and twenty healthy controls were enrolled. Sputum was collected from lower airways. IL-35 and type 2 cytokines expression from serum and sputum were measured at mRNA and protein level by real-time PCR and enzyme-linked immunosorbent assay (ELISA), respectively. The sampling and the test were repeated eight weeks after the asthma exacerbation. Results: At the time of exacerbation, IL-35 expression decreased significantly in induced sputum and serum than in the controls. The expression of IL-35 was negatively correlated with IL-4, IL-5 and IL-13 expression. The IL-35 from induced sputum increased significantly, whereas type-2 cytokines decreased significantly eight weeks after the exacerbation. Conclusion: Our results showed that decreased IL-35 was associated with type-2 cytokines in asthma exacerbations in children, suggesting that IL-35 may be a potential future drug target for asthma exacerbations.

Interleukin (IL)-35 is a newly discovered suppressive cytokine and has been shown to alleviate inflammatory and autoimmune diseases. The purpose of this study was to investigate immunomodulatory capacity of IL-35 in patients with allergic asthma.IL-35 mRNA expression levels in peripheral blood mononuclear cells (PBMCs) were detected by quantitative real-time PCR (qPCR). The frequencies of cytotoxic T cells (Tc) 1, Tc2 and Tc17 cells were measured by flow cytometry. Plasma levels of IL-35, interferon (IFN)-g, IL-4, and IL-17 were examined by enzyme-linked immunosorbent assay (ELISA). The correlations between plasma IL-35 levels and Tc1, Tc2, and Tc17 cytokine production in allergic asthmatics (n = 25) and healthy controls (n = 12) were analyzed by Pearson’s test.IL-35 protein and mRNA expression levels were down-regulated in allergic asthmatics compared with healthy controls. The frequencies of Tc2 and Tc17 cells were significantly increased in patients with asthma, and the frequency of Tc1 cells did not differ between asthmatic patients and healthy controls. Similarly, plasma levels of IL-4 and IL-17 were significantly increased in asthmatic patients, while there was no difference in IFN-g levels between allergic asthma patients and healthy controls. More importantly, plasma IL-35 protein levels were negatively correlated with the frequency of IL-4-producing CD8+ T (Tc2) cells and with the IL-4 level in patients with allergic asthma.Our results suggest that decreased circulating IL-35 levels could contribute to the pathogenesis of allergic asthma by regulating CD8+ T cells.

Background: Parkinson’s disease (PD) is increasingly recognized as a condition driven by both central and peripheral inflammatory responses, largely mediated by cytokine activity.Objective: To assess IL-35 (P35 and Ebi3 subunits) and IL-37 gene expression, along with the serum levels of IL-35 protein in patients with PD compared to healthy controls.Methods: Cytokine gene expression was measured using the qRT-PCR technique, while IL-35 serum levels were measured using the ELISA method. The data obtained were analyzed using a Bayesian regression model in the R software.Results: The results revealed that the expression of P35 gene, of the two subunits of IL-35, did not differ significantly between the two groups. However, Ebi3 and IL-37 transcript levels were significantly lower in patients compared to healthy individuals (p<0.001). In contrast,  IL-35 serum level in patients showed a significant increase compared to the control group (p=0.016).  Notably, IL-37 expression showed a negative correlation with age (p=0.004). . We also observed positive and significant correlations between the gene expression of P35 and Ebi3 (p= 0.02, r= 0.4), P35 and IL-37 (p= 0.008, r= 0.45), and Ebi3 and IL-37 (p= 0.016, r= 0.41).Conclusion: In conclusion, our study revealed a higher serum protein level of IL-35 in PD patients compared to the healthy control group. Meanwhile, gene expression levels of IL-37 and Ebi-3 were significantly reduced. These alterations in the expression of these cytokines are suggested to be partly responsible for the immune system dysregulation in this disease.

Background: Pre-eclampsia (PE) is the most common pregnancy complication affecting 2-8% of all pregnancies. PE could lead to maternal and prenatal morbidity. Imbalanced cytokine network and altered levels of several inflammatory and antiinflammatory cytokines have been reported in PE. Because of scare information regarding the roles of IL-17 and IL-35 in PE, the current study aimed to investigate the serum level of these cytokines in a group of Iranian women suffering from PE. Methods: Serum samples were collected from 100 pre-eclamptic and 100 healthy pregnant women. Patients and controls were matched for age, ethnicity and body mass index. The level of IL-35 and IL-17 were evaluated by ELISA technique. T test and one-way ANOVA with Tukey Post-Hoc test were used for analysis and p<0. 05 were assumed significant. Results: The serum level of IL-35 was increased in pre-eclamptic subjects as compared with healthy pregnant women (p<0. 001). There was no significant difference in the serum level of IL-17 between pre-eclamptic and healthy pregnant women (p=0. 73). Moreover, the results of the present study also showed that the pregnant women with severe pre-eclampsia had higher level of IL-35 in their sera when compared to those with mild form of the disease (p<0. 001). In addition, the serum level of IL-35 was significantly elevated in women with higher proteinuria (p<0. 001). Conclusion: Based on the our results, it seems that elevated levels of IL-35 in sera of pre-eclamptic women might work as a marker to evaluate the severity of the preeclampsia.